
In billboard campaign, CT health system pressures insurer. What it means for patients.
Farmington-based UConn Health is ramping up the pressure in its contract negotiations with ConnectiCare, taking out billboards at nearly a dozen prominent locations along highways in the Hartford area, urging the insurer to agree to higher reimbursement rates for services.
The billboards — along I-84 and I-91 — proclaim: 'UConn Health needs ConnectiCare to step up.'
'We're using ConnectiCare as a test case for what is coming down the line next,' Jennifer Walker, a UConn Health spokeswoman, said. 'Every other [insurer] is coming up after this. And it's going to go the same way. We letting them know that we are going to put the public pressure on it to stand up for ourselves.'
UConn Health argues its reimbursement rate is the lowest, behind all hospitals in Connecticut, despite revenue growth in the last decade and rankings that place it in the top tier of hospitals nationwide. At the same time, medical costs are rising, and Gov. Ned Lamont wants the health system — an arm of the University of Connecticut — to be more financially self-sufficient.
ConnectiCare's contract with UConn Health — the parent of John Dempsey Hospital, a network of clinics and more than 600 providers — expired on April 15. The two sides are now in a 60-day 'cooling off' period — ending June 14 —in which the two sides continue to negotiate.
On Thursday, UConn Health sent letters to ConnectiCare patients scheduled for appointments after June 14, who will either have their appointments canceled or go 'out-of-network', which can mean higher out-of-pocket costs than 'in-network.' Federal caps on out-of-pocket costs also may not apply to care that is out-of-network.
The contract negotiations cover ConnectiCare's commercial coverage, which includes employer-sponsored plans, and Medicare Advantage plans, which are sold by private insurers and offer Medicare coverage plus additional benefits. UConn Health has about 9,000 ConnectiCare patients that are affected, Walker said.
Consumers who find themselves out-of-network may be forced to find new health care providers that are in-network.
UConn Health said there can be exceptions for 'continuing care' such as chemotherapy treatments that remain in-network even in the absence of a contract. UConn Health also said it has tried to reschedule some appointments so they fall before the June 14 deadline, Walker said.
ConnectiCare, headquartered in Farmington, was acquired by California-based Molina Healthcare on Feb. 4. ConnectiCare did not respond to an email seeking comment.
UConn Health also oversees the university's medical and dental schools, plus its medical research. In the current fiscal year, UConn Health received about $193 million in state funding, or 12.5% of its total budget, UConn Health officials have said.
A six-month study last year of UConn Health's operations by a high-profile health care consulting firm found that UConn needed to generate more money from patient care in order to compete in the health care world of the future.
'We have the governor saying you can't depend on us anymore, you have to make your own money,' Walker said. 'And this is a way to close the gap on this, and not putting the burden n the taxpayers of Connecticut, making sure we are being paid as fairly as everyone else.'
Reporting by Courant Staff Writer Christopher Keating is included.
Kenneth R. Gosselin can be reached at kgosselin@courant.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
El Dorado County says South Lake Tahoe resident tests positive for plague
El Dorado County's Public Health Division announced Tuesday that a South Lake Tahoe resident has tested positive for plague and is recovering at home under medical care. Health officials said they believe the person may have been bitten by an infected flea while camping in the South Lake Tahoe area. An investigation into the exact circumstances is underway. "Plague is naturally present in many parts of California, including higher elevation areas of El Dorado County," said Kyle Fliflet, acting director of public health for the county. "It's important that individuals take precautions for themselves and their pets when outdoors, especially while walking, hiking, or camping in areas where wild rodents are present." Plague, caused by the bacterium Yersinia pestis, is typically spread by fleas that have fed on infected wild rodents such as squirrels and chipmunks, health officials said. Pets, particularly cats and dogs, can also carry plague-infected fleas into the home. Symptoms of plague generally appear within two weeks of exposure and may include fever, nausea, weakness, and swollen lymph nodes. If detected early, the illness is treatable with antibiotics. Although human cases of plague are extremely rare, they can be serious. El Dorado County said this is its first reported human case since 2020. Prior to that, the last confirmed cases in California were in 2015, involving two people exposed in Yosemite National Park. All previous patients recovered after receiving treatment. Surveillance conducted by the California Department of Public Health (CDPH) and local health agencies between 2021 and 2024 identified 41 rodents in El Dorado County that had been exposed to plague. In 2025, four additional rodents have tested positive—each found in the Tahoe Basin. El Dorado County Public Health shared the following tips to prevent exposure: Avoid contact with squirrels, chipmunks, or other rodents. Do not allow pets to interact with sick or dead rodents. Use flea control products on pets and keep them leashed when outdoors. Wear long pants and use insect repellent containing DEET when hiking or camping. Be aware of all posted warning signs. Seek medical attention if you experience symptoms after visiting an area known for plague activity.
Yahoo
2 hours ago
- Yahoo
CORRECTION – Bringing Advanced Vascular Diagnostics to the Western US with the SmartVascular Dx™ Test
IRVINE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests that addresses unmet clinical needs, announced today corrections to the second paragraph of its press release under the same headline sent out on August 8, 2025. The corrected release follows: MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now available in the Western United States. This innovative diagnostic tool aims to enhance vascular health monitoring in the region. We are also pleased to announce that we are now in-network with Blue Cross Blue Shield of Arizona, allowing us to better serve this market. Additionally, we have secured contracts that enable the reimbursement of claims through United Healthcare, Aetna, Cigna, and Humana on a nationwide basis. These claims will be reimbursed on an out-of-network basis and apply to their PPO and Medicare Advantage plans. We are happy to share that the SmartVascular Dx test is also covered by Medicare. Why SmartVascular Should Be Your Go-To Test The SmartVascular Dx test is essential for the early detection of vascular disease, which is a significant health concern in many communities. Its capabilities enable timely and targeted interventions that can significantly improve health outcomes. Furthermore, we would like to remind our partners that we have collaborated with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact mjjohnson@ 866.299.8998
Yahoo
2 hours ago
- Yahoo
This Cannabis Stock Just Transformed Into a Bitcoin Treasury Play. Should You Buy Shares Now?
It seems that companies whose products and services are not finding takers in the current market are pivoting at the drop of a hat to become Bitcoin (BTCUSD) treasury companies. While the most prominent among them has been the Michael Saylor-led MicroStrategy (MSTR), recently, two biotech companies have also 'rebranded' their business operations to load up on the world's largest cryptocurrency. Among the latest companies to join this bandwagon is cannabis company KindlyMD (NAKA). Valued at a market cap of $90 million, KindlyMD's shares have surged an impressive 742% in the year to date. More News from Barchart Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Apple Expects $1.1 Billion Tariff Hit in 4th Quarter After $800 Million Q3 Hit; CEO Tim Cook Warns 'Many Factors That Could Change' Cathie Wood Is Buying BLSH Stock After the Bullish IPO. Should You? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. About KindlyMD Founded in 2019, KindlyMD is a Utah-based healthcare provider that specializes in alternative pain management, including through medicinal cannabis use. Its licensed clinicians integrate cannabis therapy into holistic care plans, positioning the company as one of the largest Qualified Medical Providers (QMPs) within Utah's regulated medical cannabis framework. But this is all set to go up in smoke as the company has been acquired by Bitcoin-centric investment firm Nakamoto Holdings. After the merger, the combined company will operate with the KindlyMD name and with the ticker symbol NAKA. The whole transaction generated $540 million in gross proceeds through a private placement in public equity (PIPE) financing, with a $200 million convertible note also closed. Thus, with a $740 million war chest, the company aspires to acquire 1 million BTC. Commenting on the deal, CEO David Bailey said, 'Our vision is for the world's capital markets to operate on a Bitcoin standard. Today's merger represents the beginning of that journey for our company.' Bailey will continue to remain the CEO of the merged entity. Co-founder of KindlyMD and ex-CEO Tim Pickett was also upbeat about the deal, saying, 'We are thrilled to officially close our merger with Nakamoto. We've built KindlyMD on operational and innovative excellence, and we are now extending that same principle to our capital strategy. Bitcoin gives us the ability to preserve value with the same integrity we apply to delivering care.' So, that begs the question: Is NAKA stock a viable investment option now? KindlyMD Posts Widening Losses, Declining Revenues KindlyMD reported revenues of $408,527 in Q2 2025, down 36.1% from the previous year, while net losses widened dramatically to $2.4 million from $1.3 million in the year-ago period. Operational losses also increased, coming in at $2.4 million compared to just over $1 million in the same period a year ago. Net cash outflow from operating activities widened to $2.8 million from $1.1 million in the year-ago period as the company closed the quarter with a cash balance of $6.02 million. This was higher than its total debt levels of $432,978. The Bottom Line After the merger, KindlyMD and NAKA stock look like little more than a passing fad. Just a company that is hoping to take advantage of the Bitcoin treasury momentum as a trade, with no solid operational plans. Thus, avoiding NAKA shares would be a wise choice on the part of investors. On the date of publication, Pathikrit Bose did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data



